Exelixis
EXEL
#1661
Rank
NZ$21.44 B
Marketcap
NZ$79.67
Share price
0.47%
Change (1 day)
34.48%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): NZ$4.01

According to Exelixis's latest financial reports the company's current EPS (TTM) is NZ$4.09. In 2023 the company made an earnings per share (EPS) of NZ$1.12 an increase over its 2022 EPS that were of NZ$0.98.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$4.01
2023NZ$1.1214.61%
2022NZ$0.98-22.97%
2021NZ$1.27100%
2020NZ$0.64-65.09%
2019NZ$1.82-53.91%
2018NZ$3.95333.96%
2017NZ$0.91-260.61%
2016NZ-$0.57-58.75%
2015NZ-$1.37-42.45%
2014NZ-$2.395.3%
2013NZ-$2.27

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
GlaxoSmithKline
GSK
NZ$6.17 51.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
NZ$6.36 55.70%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$13.04 219.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$5.10 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$22.37 447.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
NZ$17.92 338.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$2.95-27.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
NZ-$6.30-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
NZ-$1.44-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA